169 related articles for article (PubMed ID: 25637219)
1. AXL as a modulator of sunitinib response in glioblastoma cell lines.
Martinho O; Zucca LE; Reis RM
Exp Cell Res; 2015 Mar; 332(1):1-10. PubMed ID: 25637219
[TBL] [Abstract][Full Text] [Related]
2. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Gustafsson A; Fritz HKM; Dahlbäck B
Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
[TBL] [Abstract][Full Text] [Related]
3. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
5. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib activates Axl signaling in renal cell cancer.
van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
[TBL] [Abstract][Full Text] [Related]
8. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
9. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
10. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
11. Molecular and functional characterization of reversible-sunitinib-tolerance state in human renal cell carcinoma.
Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
J Cell Mol Med; 2024 May; 28(9):e18329. PubMed ID: 38693863
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
13. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
[TBL] [Abstract][Full Text] [Related]
15. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
[TBL] [Abstract][Full Text] [Related]
16. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
[TBL] [Abstract][Full Text] [Related]
17. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
18. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
19. Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.
Poświata A; Kozik K; Miączyńska M; Zdżalik-Bielecka D
Cell Mol Life Sci; 2022 May; 79(6):316. PubMed ID: 35622156
[TBL] [Abstract][Full Text] [Related]
20. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA.
Qu L; Ding J; Chen C; Wu ZJ; Liu B; Gao Y; Chen W; Liu F; Sun W; Li XF; Wang X; Wang Y; Xu ZY; Gao L; Yang Q; Xu B; Li YM; Fang ZY; Xu ZP; Bao Y; Wu DS; Miao X; Sun HY; Sun YH; Wang HY; Wang LH
Cancer Cell; 2016 May; 29(5):653-668. PubMed ID: 27117758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
